| Clinical data | |
|---|---|
| Trade names | Haemonine, Benefix, others |
| Other names | Factor IX fraction[1] |
Factor IX concentrate, sold under the brand names Haemonine and Benefix among others, is a medication used to treat haemophilia B.[2] Specifically they are used to treat and prevent bleeding.[2] They are given by injection into a vein.[2]
Common side effects include anxiety, shortness of breath, allergic reactions, nausea, and back pain.[1] Other side effects may include angioedema and chest pain.[1] Antibodies that block its ability to work may also develop.[2] It should not be used in disseminated intravascular coagulation.[1] They are manufactured versions of factor IX made from human plasma or by recombinant methods.[2] Risks from versions made from plasma include infection.[2]
Factor IX concentrate became available in the late 1960s, while recombinant versions were approved in 1997.[2][3] It is on the World Health Organization's List of Essential Medicines.[4] In the United Kingdom 1,000 units of the recombinant or plasma derived versions costs the NHS about £600 as of 2023.[5] Longer acting versions are also available.[2]
References
edit- ^ a b c d e "Factor IX fraction, dried [Specialist drug]". BNF. Archived from the original on 16 September 2023. Retrieved 13 September 2023.
- ^ a b c d e f g h i j Konkle, Barbara A (9 February 2023). Hemophilia B. GeneReviews. Archived from the original on 20 October 2019. Retrieved 13 September 2023.
- ^ "Hemophilia: From Plasma to Recombinant Factors". 2008. Archived from the original on 29 May 2023. Retrieved 13 September 2023.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "Factor IX fraction, dried [Specialist drug] Medicinal forms". BNF. Archived from the original on 13 September 2023. Retrieved 13 September 2023.